Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABDULHAY ALBIRINI

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1174509160
CMS profile
53620
Location
ZANESVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$12,296.04

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABDULHAY ALBIRINI

NPI 1174509160 · CMS profile ID 53620

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

ZANESVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174509160?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABDULHAY ALBIRINI, NPI 1174509160, CMS profile ID 53620. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174509160?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ABDULHAY ALBIRINI, NPI 1174509160, CMS profile ID 53620. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174509160?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ABDULHAY ALBIRINI, NPI 1174509160, CMS profile ID 53620, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1174509160?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $12,296.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $18.9507/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086720997 CMS
Lexicon Pharmaceuticals, Inc. $23.6207/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081719509 CMS
Edwards Lifesciences Corporation $22.6006/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138824208 CMS
Lexicon Pharmaceuticals, Inc. $22.6706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081719507 CMS
ShockWave Medical, Inc $16.8806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152991499 CMS
ShockWave Medical, Inc $5.8406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152991287 CMS
Edwards Lifesciences Corporation $23.4006/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138824206 CMS
Esperion Therapeutics, Inc. $14.9906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129425578 CMS
Abbott Laboratories $23.2606/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124881396 CMS
Boston Scientific Corporation $16.3405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092494520 CMS
Esperion Therapeutics, Inc. $13.0805/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129425576 CMS
Amgen Inc. $19.6905/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111512898 CMS
Kiniksa Pharmaceuticals International, plc $13.2605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154866589 CMS
PFIZER INC. $16.9805/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131462388 CMS
Becton, Dickinson and Company $24.6405/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127633446 CMS
Amgen Inc. $18.7505/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117491376 CMS
Inari Medical, Inc. $31.8705/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056692 CMS
Boston Scientific Corporation $17.2505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092494522 CMS
Edwards Lifesciences Corporation $45.9304/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138824202 CMS
E.R. Squibb & Sons, L.L.C. $13.6704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101200916 CMS
Amgen Inc. $18.2904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111512896 CMS
Medtronic, Inc. $21.4304/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247150994 CMS
Penumbra, Inc. $70.0204/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1076205942 CMS
Penumbra, Inc. $42.3104/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1076205940 CMS
Penumbra, Inc. $120.1704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1076230580 CMS
Penumbra, Inc. $265.4804/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1076232308 CMS
ShockWave Medical, Inc $46.5304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152981086 CMS
ShockWave Medical, Inc $154.5304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152982636 CMS
Boston Scientific Corporation $2.3004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092494510 CMS
ShockWave Medical, Inc $15.8303/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152982352 CMS
Cook Medical LLC $20.3003/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118342081 CMS
AstraZeneca Pharmaceuticals LP $16.8903/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104331954 CMS
E.R. Squibb & Sons, L.L.C. $13.6703/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101200910 CMS
Novo Nordisk Inc $16.0103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096697056 CMS
Terumo Medical Corporation $24.9102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151759599 CMS
Amgen Inc. $17.8602/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111512894 CMS
PFIZER INC. $14.0602/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131453805 CMS
AstraZeneca Pharmaceuticals LP $13.2002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105518927 CMS
Amgen Inc. $24.8502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111512892 CMS
Cook Medical LLC $10.0302/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118325764 CMS
Silk Road Medical, Inc. $16.8202/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082276528 CMS
Inari Medical, Inc. $63.8701/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056684 CMS
Inari Medical, Inc. $63.8701/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056686 CMS
Inari Medical, Inc. $413.1001/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056688 CMS
Inari Medical, Inc. $26.2101/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056690 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117901774 CMS
Inari Medical, Inc. $166.6901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056680 CMS
Inari Medical, Inc. $166.6901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140056682 CMS
ShockWave Medical, Inc $119.9101/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152986556 CMS
Amgen Inc. $24.2501/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111512890 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,313.35 94
PY2020 $774.11 53
PY2021 $1,298.98 67
PY2022 $1,741.66 78
PY2023 $4,792.71 106
PY2024 $12,296.04 108
PY2025 $1,951.01 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $49,217.32 14
PY2024 Principal investigator $68,435.00 15
PY2023 Principal investigator $39,190.00 7
PY2022 Principal investigator $8,540.08 14
PY2021 Principal investigator $17,217.12 8
PY2020 Principal investigator $9,009.70 10
PY2019 Principal investigator $22,101.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $957.00 12/19/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262044
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 12/12/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262071
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,662.32 12/08/2025 Non-covered Recipient Entity
GENESIS HEALTHCARE SYSTEM
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190313821
Principal investigator 1 Janssen Research & Development, LLC $3,813.00 11/19/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262019
Principal investigator 1 Janssen Research & Development, LLC $2,536.00 11/07/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262011
Principal investigator 1 Janssen Research & Development, LLC $1,255.00 09/19/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175261984
Principal investigator 1 Janssen Research & Development, LLC $3,530.00 08/25/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175261973
Principal investigator 1 Janssen Research & Development, LLC $11,450.00 08/13/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262000
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 06/20/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262025
Principal investigator 1 Janssen Research & Development, LLC $3,530.00 05/21/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175261992
Principal investigator 1 Janssen Research & Development, LLC $1,281.00 04/23/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262078
Principal investigator 1 Janssen Research & Development, LLC $1,281.00 03/21/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262060
Principal investigator 1 Janssen Research & Development, LLC $3,582.00 02/19/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262052
Principal investigator 1 Janssen Research & Development, LLC $300.00 01/06/2025 Non-covered Recipient Entity
Genesis Hlthcare Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262036